Biogen to Acquire Apellis Pharmaceuticals After 82.4% Shareholder Acceptance

Biogen has announced the successful completion of its tender offer for Apellis Pharmaceuticals, with approximately 82.4% of outstanding shares tendered by stockholders. Under the agreement, shareholders are set to receive $41.00 per share in cash, alongside a contingent value right (CVR) worth up to an additional $4.00. The merger is anticipated to close on May 14, 2026, which will result in Apellis becoming a wholly-owned subsidiary of Biogen and its subsequent delisting from the Nasdaq Global Select Market.

This acquisition aligns with a broader trend of consolidation within the biotechnology sector as major players seek to bolster their specialized drug pipelines. Similar to recent industry moves, such as Pfizer’s acquisition of Seagen, Biogen’s strategy emphasizes acquiring innovative therapeutic platforms. Per market data, the $41.00 offer price was structured to secure institutional support, a goal achieved by surpassing the 80% acceptance threshold required to bypass a full stockholder vote.

Investors should note that the merger is expected to finalize on May 14, 2026, marking the final trading day for APLS. Looking ahead, the broader market sentiment will be influenced by upcoming central bank commentary, including Fed Cook’s speech on May 8, 2026, which may impact financing outlooks for future M&A activity. Additionally, the Michigan Consumer Sentiment data scheduled for release on May 8 will provide further context for overall market stability during this transition.